Summary of adverse events (all grades) and treatment discontinuation in 18 patients
. | No. (%) . |
---|---|
Adverse events | |
Neuropathic pain | 1 (6) |
Peripheral neuropathy | 2 (11) |
Neutropenia | 1 (6) |
Headache | 1 (6) |
Hypertension | 1 (6) |
Infections | 2 (11) |
Thrombocytopenia | 7 (39) |
Platelet count 50 × 109/L to less than 150 × 109/L | 5 (28) |
Platelet count 25 × 109/L to less than 50 × 109/L | 2 (11) |
Serious adverse events | |
Death due to progressive disease | 1 (6) |
Adverse events leading to discontinuation | |
Progressive disease | 6 (33) |
Neuropathic pain | 1 (6) |
Peripheral neuropathy | 1 (6) |
. | No. (%) . |
---|---|
Adverse events | |
Neuropathic pain | 1 (6) |
Peripheral neuropathy | 2 (11) |
Neutropenia | 1 (6) |
Headache | 1 (6) |
Hypertension | 1 (6) |
Infections | 2 (11) |
Thrombocytopenia | 7 (39) |
Platelet count 50 × 109/L to less than 150 × 109/L | 5 (28) |
Platelet count 25 × 109/L to less than 50 × 109/L | 2 (11) |
Serious adverse events | |
Death due to progressive disease | 1 (6) |
Adverse events leading to discontinuation | |
Progressive disease | 6 (33) |
Neuropathic pain | 1 (6) |
Peripheral neuropathy | 1 (6) |